These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11466921)

  • 1. [The use of aminoglycosides].
    Järvinen A
    Duodecim; 1998; 114(6):563-70. PubMed ID: 11466921
    [No Abstract]   [Full Text] [Related]  

  • 2. Do we still need the aminoglycosides?
    Durante-Mangoni E; Grammatikos A; Utili R; Falagas ME
    Int J Antimicrob Agents; 2009 Mar; 33(3):201-5. PubMed ID: 18976888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aminoglycoside toxicity. Pathomechanisms, clinical management and means of prevention].
    Lautermann J; Schacht J; Jahnke K
    HNO; 2003 Apr; 51(4):344-51; quiz 352. PubMed ID: 12682739
    [No Abstract]   [Full Text] [Related]  

  • 4. [Aminoglycosides and polymyxins].
    Molina J; Cordero E; Palomino J; Pachón J
    Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):178-88. PubMed ID: 19303668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined cephalosporin aminoglycoside therapy in gram-negative sepsis. The choice of cephalosporin.
    Mészáros J; Tołłoczko T; Stachlewska E; Tyc Z; Jeljaszewicz J
    J Chemother; 1989 Jul; 1(4 Suppl):828-9. PubMed ID: 16312658
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of colistin in children.
    Tamma PD; Lee CK
    Pediatr Infect Dis J; 2009 Jun; 28(6):534-5. PubMed ID: 19483519
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Returning to the pre-antibiotic era in the critically ill: the XDR problem.
    Paterson DL; Lipman J
    Crit Care Med; 2007 Jul; 35(7):1789-91. PubMed ID: 17581370
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tobramycin in pediatrics. Report of 24 cases].
    Fournet JP; Huault G; Castaing H; Mariel C
    Ann Pediatr (Paris); 1976 Apr; 23(4):293-9. PubMed ID: 16104222
    [No Abstract]   [Full Text] [Related]  

  • 10. Single versus combined antibiotic therapy for gram-negative infections.
    Klibanov OM; Raasch RH; Rublein JC
    Ann Pharmacother; 2004 Feb; 38(2):332-7. PubMed ID: 14742774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic drug monitoring of aminoglycosides as an additional pharmacy service].
    Kilian R
    Med Monatsschr Pharm; 2003 May; 26(5):152-5. PubMed ID: 12784503
    [No Abstract]   [Full Text] [Related]  

  • 12. Neonatal sepsis in hospital-born babies.
    Butt T; Ahmad RN; Usman M
    J Coll Physicians Surg Pak; 2004 Feb; 14(2):125; author reply 125-6. PubMed ID: 15228882
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibiotic resistance.
    Cuddy ML
    J Pract Nurs; 2005; 55(3):11-7; quiz 18. PubMed ID: 16355726
    [No Abstract]   [Full Text] [Related]  

  • 14. [Virulence blocking antibiotics. Anti-bacterial agents with completely new action mechanisms].
    Sundin C; Elofsson M; Wolf-Watz H; Rosell S
    Lakartidningen; 2009 Sep 30-Oct 6; 106(40):2543-5. PubMed ID: 19908625
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular insights into aminoglycoside action and resistance.
    Magnet S; Blanchard JS
    Chem Rev; 2005 Feb; 105(2):477-98. PubMed ID: 15700953
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria.
    Teng CB; Koh PT; Lye DC; Ang BS
    Int J Antimicrob Agents; 2008 Jan; 31(1):80-2. PubMed ID: 17920246
    [No Abstract]   [Full Text] [Related]  

  • 17. Aminoglycosides: the complex problem of antibiotic mechanisms and clinical applications.
    Montie T; Patamasucon P
    Eur J Clin Microbiol Infect Dis; 1995 Feb; 14(2):85-7. PubMed ID: 7758491
    [No Abstract]   [Full Text] [Related]  

  • 18. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms.
    Kashuba AD; Bertino JS; Nafziger AN
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1842-4. PubMed ID: 9661031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
    Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
    J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.